News briefing: Novartis eyes expansion for Eylea rival with PhIII results; Dupixent obtains BTD for EoE
Novartis reported positive topline results in a Phase III for its Eylea rival, a sign that the company is pushing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
